ID   IGR-CaP1
AC   CVCL_A018
SY   Institut Gustave Roussy-Carcinoma Pancreas 1
DR   cancercelllines; CVCL_A018
DR   IARC_TP53; 28239
DR   Wikidata; Q54897375
RX   Patent=US8674172;
RX   PubMed=20974126;
RX   PubMed=24525428;
RX   PubMed=27198502;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4126.
CC   Doubling time: 43 hours (PubMed=20974126).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (PubMed=20974126).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): Patent=US8674172; PubMed=20974126
ST   Amelogenin: X
ST   CSF1PO: 11,14,16
ST   D13S317: 8,10
ST   D16S539: 11,12,13
ST   D18S51: 14,15,16
ST   D19S433: 13,14
ST   D21S11: 26,30.2
ST   D2S1338: 17,24,25
ST   D3S1358: 14,15
ST   D5S818: 12,13
ST   D7S820: 9.1,10.1,11.2
ST   D8S1179: 13,14,15,16,17
ST   FGA: 20,21,25,26
ST   TH01: 7,8,9.3
ST   TPOX: 8,10,11
ST   vWA: 16,20,21
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 15
//
RX   Patent=US8674172;
RA   Chauchereau A., Fizazi K., Gaudin C., Al Nakouzi N., Benard J.;
RT   "Prostate cancer cell lines and their use in screening method.";
RL   Patent number US8674172, 18-Mar-2014.
//
RX   PubMed=20974126; DOI=10.1016/j.yexcr.2010.10.012;
RA   Chauchereau A., Al Nakouzi N., Gaudin C., Le Moulec S., Compagno D.,
RA   Auger N., Benard J., Opolon P., Rozet F., Validire P., Fromont G.,
RA   Fizazi K.;
RT   "Stemness markers characterize IGR-CaP1, a new cell line derived from
RT   primary epithelial prostate cancer.";
RL   Exp. Cell Res. 317:262-275(2011).
//
RX   PubMed=24525428; DOI=10.18632/oncotarget.1574;
RA   Al Nakouzi N., Cotteret S., Commo F., Gaudin C., Rajpar S., Dessen P.,
RA   Vielh P., Fizazi K., Chauchereau A.;
RT   "Targeting CDC25C, PLK1 and CHEK1 to overcome docetaxel resistance
RT   induced by loss of LZTS1 in prostate cancer.";
RL   Oncotarget 5:667-678(2014).
//
RX   PubMed=27198502; DOI=10.15252/emmm.201506059;
RA   Al Nakouzi N., Wang C.K.-D., Beraldi E., Jager W., Ettinger S.,
RA   Fazli L., Nappi L., Bishop J., Zhang F., Chauchereau A., Loriot Y.,
RA   Gleave M.E.;
RT   "Clusterin knockdown sensitizes prostate cancer cells to taxane by
RT   modulating mitosis.";
RL   EMBO Mol. Med. 8:761-778(2016).
//